Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin
Atorvastatin is a plasma cholesterol-lowering drug which applies antifungal effects by inhibiting the production of yeast cell wall ergostrol. The aim of present study was to investigate in-vitro susceptibility of candida species to atorvastatin, in comparison to nystatin and fluconazole. Minimum in...
Gespeichert in:
| Veröffentlicht in: | Medicine and pharmacy reports 2019-10, Vol.92 (4), p.368-373 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 373 |
|---|---|
| container_issue | 4 |
| container_start_page | 368 |
| container_title | Medicine and pharmacy reports |
| container_volume | 92 |
| creator | Esfahani, Ava Nasr Golestannejad, Zahra Khozeimeh, Faezeh Dehghan, Parvin Maheronnaghsh, Mehrnoosh Zarei, Zahra |
| description | Atorvastatin is a plasma cholesterol-lowering drug which applies antifungal effects by inhibiting the production of yeast cell wall ergostrol. The aim of present study was to investigate in-vitro susceptibility of candida species to atorvastatin, in comparison to nystatin and fluconazole.
Minimum inhibitory concentrations (MIC) and minimum fungicidal concentrations (MFC) were determined using serial dilution. Candida strains isolated from 35 patients receiving cancer chemotherapy in Isfahan, Seyyed-al-Shohada Hospital and analyzed by Kruskal-Wallis and Mann Whitney statistical methods.
Candida isolates included 5 strains,
and
All five strains appeared to be resistant to nystatin and fluconazole but sensitive to atorvastatin with no statistically significant difference. The MFC of atorvastatin was significantly lower in comparison to both nystatin and fluconazole for all five strains (p value |
| doi_str_mv | 10.15386/mpr-1209 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6853048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2316785209</sourcerecordid><originalsourceid>FETCH-LOGICAL-c255t-908e49165a4b2dc7acd84a47dca2a6edc25f705696dfb0615c262438e8e5730b3</originalsourceid><addsrcrecordid>eNpVkUtLLDEQRoNcUVEX_gHJ0rtozaPz6I0wDL5AdKPrUJNOj7l0J22SFvTX2zpe0VUV1OFUUR9CR5ScUsG1PBvGVFFGmi20x6TUFRGK_fnoCauIJmoXHeb8jxDCKG8aqnfQLqdKkJqrPWQXofhuCmvoses6ZwuOHV6UmF4gFyg-YFiDD7ngJYTWt4Dz6Kx3Gc8jG4cRks8x4BLxZT_ZGOAt9g7PLL573RgO0HYHfXaHX3UfPV5ePCyvq9v7q5vl4rayTIhSNUS7uqFSQL1irVVgW11DrVoLDKRrZ6pTRMhGtt2KSCosk6zm2mknFCcrvo_ON95xWg0z70JJ0Jsx-QHSq4ngze9J8E9mHV-M1IKTWs-Cky9Bis-Ty8UMPlvX9xBcnLJhnEqlxfzrGf27QW2KOSfXfa-hxHzmYuZcDN2wxz_v-ib_p8DfAfnhiu0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2316785209</pqid></control><display><type>article</type><title>Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin</title><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Esfahani, Ava Nasr ; Golestannejad, Zahra ; Khozeimeh, Faezeh ; Dehghan, Parvin ; Maheronnaghsh, Mehrnoosh ; Zarei, Zahra</creator><creatorcontrib>Esfahani, Ava Nasr ; Golestannejad, Zahra ; Khozeimeh, Faezeh ; Dehghan, Parvin ; Maheronnaghsh, Mehrnoosh ; Zarei, Zahra</creatorcontrib><description>Atorvastatin is a plasma cholesterol-lowering drug which applies antifungal effects by inhibiting the production of yeast cell wall ergostrol. The aim of present study was to investigate in-vitro susceptibility of candida species to atorvastatin, in comparison to nystatin and fluconazole.
Minimum inhibitory concentrations (MIC) and minimum fungicidal concentrations (MFC) were determined using serial dilution. Candida strains isolated from 35 patients receiving cancer chemotherapy in Isfahan, Seyyed-al-Shohada Hospital and analyzed by Kruskal-Wallis and Mann Whitney statistical methods.
Candida isolates included 5 strains,
and
All five strains appeared to be resistant to nystatin and fluconazole but sensitive to atorvastatin with no statistically significant difference. The MFC of atorvastatin was significantly lower in comparison to both nystatin and fluconazole for all five strains (p value<0.05). There was no significant difference between the MFCs of 5 strains for fluconazole and atorvastatin. However, MFC of nystatin differed significantly for
and
(p=0.007).
The results showed that all strains were sensitive to atorvastatin and resistant to nystatin and fluconazole. Atorvastatin MIC for
and
was equivalent to its serum level used to treat hyperlipidemia and was above such level for both
and
.</description><identifier>ISSN: 2602-0807</identifier><identifier>EISSN: 2668-0572</identifier><identifier>DOI: 10.15386/mpr-1209</identifier><identifier>PMID: 31750437</identifier><language>eng</language><publisher>Romania: Iuliu Hatieganu University of Medicine and Pharmacy</publisher><subject>Original Research</subject><ispartof>Medicine and pharmacy reports, 2019-10, Vol.92 (4), p.368-373</ispartof><rights>2019</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c255t-908e49165a4b2dc7acd84a47dca2a6edc25f705696dfb0615c262438e8e5730b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853048/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853048/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31750437$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Esfahani, Ava Nasr</creatorcontrib><creatorcontrib>Golestannejad, Zahra</creatorcontrib><creatorcontrib>Khozeimeh, Faezeh</creatorcontrib><creatorcontrib>Dehghan, Parvin</creatorcontrib><creatorcontrib>Maheronnaghsh, Mehrnoosh</creatorcontrib><creatorcontrib>Zarei, Zahra</creatorcontrib><title>Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin</title><title>Medicine and pharmacy reports</title><addtitle>Med Pharm Rep</addtitle><description>Atorvastatin is a plasma cholesterol-lowering drug which applies antifungal effects by inhibiting the production of yeast cell wall ergostrol. The aim of present study was to investigate in-vitro susceptibility of candida species to atorvastatin, in comparison to nystatin and fluconazole.
Minimum inhibitory concentrations (MIC) and minimum fungicidal concentrations (MFC) were determined using serial dilution. Candida strains isolated from 35 patients receiving cancer chemotherapy in Isfahan, Seyyed-al-Shohada Hospital and analyzed by Kruskal-Wallis and Mann Whitney statistical methods.
Candida isolates included 5 strains,
and
All five strains appeared to be resistant to nystatin and fluconazole but sensitive to atorvastatin with no statistically significant difference. The MFC of atorvastatin was significantly lower in comparison to both nystatin and fluconazole for all five strains (p value<0.05). There was no significant difference between the MFCs of 5 strains for fluconazole and atorvastatin. However, MFC of nystatin differed significantly for
and
(p=0.007).
The results showed that all strains were sensitive to atorvastatin and resistant to nystatin and fluconazole. Atorvastatin MIC for
and
was equivalent to its serum level used to treat hyperlipidemia and was above such level for both
and
.</description><subject>Original Research</subject><issn>2602-0807</issn><issn>2668-0572</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkUtLLDEQRoNcUVEX_gHJ0rtozaPz6I0wDL5AdKPrUJNOj7l0J22SFvTX2zpe0VUV1OFUUR9CR5ScUsG1PBvGVFFGmi20x6TUFRGK_fnoCauIJmoXHeb8jxDCKG8aqnfQLqdKkJqrPWQXofhuCmvoses6ZwuOHV6UmF4gFyg-YFiDD7ngJYTWt4Dz6Kx3Gc8jG4cRks8x4BLxZT_ZGOAt9g7PLL573RgO0HYHfXaHX3UfPV5ePCyvq9v7q5vl4rayTIhSNUS7uqFSQL1irVVgW11DrVoLDKRrZ6pTRMhGtt2KSCosk6zm2mknFCcrvo_ON95xWg0z70JJ0Jsx-QHSq4ngze9J8E9mHV-M1IKTWs-Cky9Bis-Ty8UMPlvX9xBcnLJhnEqlxfzrGf27QW2KOSfXfa-hxHzmYuZcDN2wxz_v-ib_p8DfAfnhiu0</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Esfahani, Ava Nasr</creator><creator>Golestannejad, Zahra</creator><creator>Khozeimeh, Faezeh</creator><creator>Dehghan, Parvin</creator><creator>Maheronnaghsh, Mehrnoosh</creator><creator>Zarei, Zahra</creator><general>Iuliu Hatieganu University of Medicine and Pharmacy</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20191001</creationdate><title>Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin</title><author>Esfahani, Ava Nasr ; Golestannejad, Zahra ; Khozeimeh, Faezeh ; Dehghan, Parvin ; Maheronnaghsh, Mehrnoosh ; Zarei, Zahra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c255t-908e49165a4b2dc7acd84a47dca2a6edc25f705696dfb0615c262438e8e5730b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Original Research</topic><toplevel>online_resources</toplevel><creatorcontrib>Esfahani, Ava Nasr</creatorcontrib><creatorcontrib>Golestannejad, Zahra</creatorcontrib><creatorcontrib>Khozeimeh, Faezeh</creatorcontrib><creatorcontrib>Dehghan, Parvin</creatorcontrib><creatorcontrib>Maheronnaghsh, Mehrnoosh</creatorcontrib><creatorcontrib>Zarei, Zahra</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine and pharmacy reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Esfahani, Ava Nasr</au><au>Golestannejad, Zahra</au><au>Khozeimeh, Faezeh</au><au>Dehghan, Parvin</au><au>Maheronnaghsh, Mehrnoosh</au><au>Zarei, Zahra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin</atitle><jtitle>Medicine and pharmacy reports</jtitle><addtitle>Med Pharm Rep</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>92</volume><issue>4</issue><spage>368</spage><epage>373</epage><pages>368-373</pages><issn>2602-0807</issn><eissn>2668-0572</eissn><abstract>Atorvastatin is a plasma cholesterol-lowering drug which applies antifungal effects by inhibiting the production of yeast cell wall ergostrol. The aim of present study was to investigate in-vitro susceptibility of candida species to atorvastatin, in comparison to nystatin and fluconazole.
Minimum inhibitory concentrations (MIC) and minimum fungicidal concentrations (MFC) were determined using serial dilution. Candida strains isolated from 35 patients receiving cancer chemotherapy in Isfahan, Seyyed-al-Shohada Hospital and analyzed by Kruskal-Wallis and Mann Whitney statistical methods.
Candida isolates included 5 strains,
and
All five strains appeared to be resistant to nystatin and fluconazole but sensitive to atorvastatin with no statistically significant difference. The MFC of atorvastatin was significantly lower in comparison to both nystatin and fluconazole for all five strains (p value<0.05). There was no significant difference between the MFCs of 5 strains for fluconazole and atorvastatin. However, MFC of nystatin differed significantly for
and
(p=0.007).
The results showed that all strains were sensitive to atorvastatin and resistant to nystatin and fluconazole. Atorvastatin MIC for
and
was equivalent to its serum level used to treat hyperlipidemia and was above such level for both
and
.</abstract><cop>Romania</cop><pub>Iuliu Hatieganu University of Medicine and Pharmacy</pub><pmid>31750437</pmid><doi>10.15386/mpr-1209</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2602-0807 |
| ispartof | Medicine and pharmacy reports, 2019-10, Vol.92 (4), p.368-373 |
| issn | 2602-0807 2668-0572 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6853048 |
| source | PubMed Central; PubMed Central Open Access |
| subjects | Original Research |
| title | Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T07%3A54%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antifungal%20effect%20of%20Atorvastatin%20against%20Candida%20species%20in%20comparison%20to%20Fluconazole%20and%20Nystatin&rft.jtitle=Medicine%20and%20pharmacy%20reports&rft.au=Esfahani,%20Ava%20Nasr&rft.date=2019-10-01&rft.volume=92&rft.issue=4&rft.spage=368&rft.epage=373&rft.pages=368-373&rft.issn=2602-0807&rft.eissn=2668-0572&rft_id=info:doi/10.15386/mpr-1209&rft_dat=%3Cproquest_pubme%3E2316785209%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2316785209&rft_id=info:pmid/31750437&rfr_iscdi=true |